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Regular Article
CLINICAL TRIALS AND OBSERVATIONS

Carﬁlzomib, lenalidomide, and dexamethasone plus
transplant in newly diagnosed multiple myeloma
Jagoda K. Jasielec,1 Tadeusz Kubicki,1,2 Noopur Raje,3 Ravi Vij,4 Donna Reece,5 Jesus Berdeja,6 Benjamin A. Derman,1 Cara A. Rosenbaum,1,7
Paul Richardson,8 Sandeep Gurbuxani,1 Sarah Major,1 Brittany Wolfe,1 Andrew T. Stefka,1 Leonor Stephens,1 Kathryn M. Tinari,1 Tyler Hycner,1
Alexandra E. Rojek,1 Dominik Dytfeld,1,2 Kent A. Grifﬁth,9 Todd M. Zimmerman,1,10 and Andrzej J. Jakubowiak1

In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell
transplantation (ASCT) into a carﬁlzomib-lenalidomide-dexamethasone (KRd) regimen for
l Extended KRd plus
patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with
transplant for NDMM
NDMM received 4 cycles of KRd induction, ASCT, 4 cycles of KRd consolidation, and 10 cycles
patients provided
high-quality responses
of KRd maintenance. The primary end point was rate of stringent complete response (sCR)
with prolonged
after 8 cycles of KRd with a predeﬁned threshold of ‡50% to support further study. Seventydisease control and
six patients were enrolled with a median age of 59 years (range, 40-76 years), and 35.5% had
manageable
tolerability.
high-risk cytogenetics. The primary end point was met, with an sCR rate of 60% after 8 cycles.
Depth of response improved over time. On intent-to-treat (ITT), the sCR rate reached 76%.
l Responses were rapid,
The rate of minimal residual disease (MRD) negativity using modiﬁed ITT was 70% according
but achieving best
response required
to next-generation sequencing (<1025 sensitivity). After median follow-up of 56 months,
extended KRd
5-year progression-free survival (PFS) and overall survival (OS) rates were 72% and 84% for
treatment.
ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with high-risk
cytogenetics. For high-risk patients who were MRD negative, 5-year rates were 77% and
81%. Grade 3 to 4 adverse events included neutropenia (34%), lymphopenia (32%), infection (22%), and cardiac events
(3%). There was no grade 3 to 4 peripheral neuropathy. Patients with NDMM treated with KRd with ASCT achieved high
rates of sCR and MRD-negative disease at the end of KRd consolidation. Extended KRd maintenance after consolidation
contributed to deepening of responses and likely to prolonged PFS and OS. Safety and tolerability were manageable. This
trial was registered at www.clinicaltrials.gov as #NCT01816971. (Blood. 2020;136(22):2513-2523)
KEY POINTS

Introduction
The treatment of multiple myeloma (MM) rapidly evolved with
the introduction of immunomodulatory drugs (IMiDs) and
proteasome inhibitors (PIs). The development of triplet combinations with these agents, clearly established as superior to
doublets, has transformed the standard of care.1-4 Several triplet
combinations are now used as induction therapy for patients
with newly diagnosed MM (NDMM), including regimens with PIchemotherapy or PI-IMiD backbones. PI-IMiD–based triplets
have become a preferred treatment option because of their
improved response and survival outcomes compared with
previous standards of care.5
The combination of lenalidomide-bortezomib-dexamethasone
(RVd) is one of the more commonly used ﬁrst-line induction

© 2020 by The American Society of Hematology

regimens and has shown consistently high activity across
studies.2,6-8 The arrival of next-generation PIs brought additional PI-IMiD–based triplets to the clinic, including carﬁlzomiblenalidomide-dexamethasone (KRd).9 RVd and KRd were the ﬁrst
regimens with 100% response rates, with some of the highest
rates of complete response (CR) at that time.7,9 However, a
preferred PI-IMiD–based regimen has not been clearly established in the ﬁrst-line setting.10,11
Ongoing efforts to further improve treatment outcome in patients with NDMM include incorporation of monoclonal
antibodies12-14 and/or autologous stem cell transplantation
(ASCT) into treatment with novel regimens.14-18 Results from
randomized trials have shown that incorporation of ASCT into
RVd treatment improved clinical outcomes compared with RVd
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without ASCT, which supports the use of ASCT with novel
regimens as a standard of care.17 In addition, there is emerging
evidence that duration of treatment with multidrug regimens
plays a role. Although the optimal duration of initial treatment is
not well established, recent studies in transplant-ineligible patients indicate that extended treatment improves disease control
compared with shorter, ﬁxed durations, although a signiﬁcant
overall survival (OS) beneﬁt has not been demonstrated.19-21 In
studies of patients undergoing transplantation with multidrug
induction and consolidation, the duration of triplet regimens
such as RVd and KRd has generally been limited to 3 to 6 cycles
of induction with 2 to 4 cycles of consolidation.7,8,17,22

allowed for treatment failures. Conditioning chemotherapy
consisted of melphalan 200 mg/m2 IV. Participating centers
followed their standard protocol for administering autologous
peripheral stem cells, hydration, and prophylaxis measures.

Promising results have been reported with extended KRd (24
cycles) in patients with NDMM who were transplant ineligible, or
they were eligible but they deferred ASCT.9 In this phase 2
multicenter Multiple Myeloma Research Consortium (MMRC)
study, we show that incorporation of ASCT into a KRd regimen
provided high rates of CR and stringent CR (sCR) after consolidation, with responses improving during extended KRd maintenance, likely contributing to observed prolonged progressionfree survival (PFS) and OS outcomes.

For KRd maintenance (cycles 9 to 18), carﬁlzomib was administered at the last tolerated consolidation dose on days 1, 2, 15,
and 16. Lenalidomide and dexamethasone were administered at
the last tolerated consolidation doses using the same dose
schedules. After 18 KRd cycles, maintenance treatment was
continued with single-agent lenalidomide at the last tolerated
dose and schedule until disease progression or unacceptable
toxicity.

KRd consolidation (cycles 5 to 8) was started within 70 to 90 days
or ,120 days after ASCT. Carﬁlzomib was administered on the
same schedule as induction therapy at the last tolerated induction dose. Lenalidomide was restarted at 15 mg on days 1 to
21 for cycle 5 and then escalated to the last tolerated dose.
Dexamethasone was administered at the same weekly dosing
schedule as induction therapy but at a dose of 20 mg.

Patients and methods
Study design and participants
This was a multicenter, open label, single-arm, phase 2 study.
Patients were recruited from 5 MMRC sites in North America.
Transplant-eligible patients age 18 years or older with NDMM
who required systemic chemotherapy per International Myeloma Working Group (IMWG) uniform criteria were eligible.23
There was no upper age limit provided patients met transplant
eligibility requirements. Full eligibility criteria are described in
the supplemental Information, available on the Blood Web site.
The study was conducted in accordance with US Food and Drug
Administration and International Conference on Harmonization
Guidelines for Good Clinical Practice, the Declaration of Helsinki, Health Canada, and any applicable health authority. The
study protocol was approved by the institutional review boards
or ethics committees of participating institutions. All patients
provided written informed consent.

Treatment
Patients received 4 cycles (28 days per cycle) of KRd induction
followed by ASCT, 4 cycles of KRd consolidation, and then
10 cycles of KRd maintenance, for a total of 18 cycles of KRd.
For induction, carﬁlzomib was administered intravenously (IV)
on days 1, 2, 8, 9, 15, and 16; the dose was 20 mg/m2 for days 1
and 2 of cycle 1 and then 36 mg/m2 thereafter. The carﬁlzomib
dosing strategy was based on ﬁndings from the previous phase
1/2 study of KRd without transplantation.9 Lenalidomide was
administered orally at 25 mg on days 1 to 21 of each cycle, and
dexamethasone was given orally or IV at 40 mg on days 1, 8, 15,
and 22 of each cycle. Dose modiﬁcations were permitted to
manage toxicity (see supplemental Information for dose reduction
guidance). The dosing and design of this study were similar to
those of the previous KRd study without ASCT9 to help us better
understand the potential impact of incorporating ASCT.
After KRd induction, granulocyte colony-stimulating factor and
plerixafor were given for stem cell mobilization 2 to 4 weeks after
the last dose of lenalidomide; alternative mobilization was
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Disease-related tests were performed at baseline and on day 1 of
each cycle, including M-protein by serum and/or urine protein
electrophoresis, quantitative immunoglobulins, and immunoglobulin free light chains. Imaging was used according to the
current IMWG recommendations, and response assessments
were made according to IMWG uniform response criteria.24,25
Samples for minimal residual disease (MRD) analysis were
obtained at landmark time points: after 8 cycles, after 18 cycles,
and then at 1, 2, 3, and 5 years of single-agent lenalidomide
maintenance. Samples were analyzed by next-generation sequencing at Adaptive Biotechnologies (Seattle, WA) with ,1025
sensitivity. MRD negativity was determined by IMWG criteria
(patients with CR or better and with at least 1025 MRD
negativity).25 Positron emission tomography-computed tomography scans were performed at landmark time points in patients
with MRD-negative status according to IMWG recommendations.
Adverse events (AEs) were graded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0. AEs were collected from the day of treatment
initiation through 30 days after the last dose or at the initiation of
a new anticancer therapy. Per protocol, AEs were not collected
during ASCT (stem cell collection through start of consolidation)
and during single-agent lenalidomide maintenance.

Study end points
The primary end point was rate of sCR after 8 cycles of KRd.
Secondary end points included overall response rate, PFS, and
OS. Exploratory end points included evaluation of MRD rates at
the indicated landmark time points.

Statistical analysis
For the primary end point, we estimated that 53 to 70 patients
would be needed to interrogate the hypothesis that incorporation of ASCT into extended KRd would improve the sCR
rate from 30% reported at the end of 8 cycles in the historical
phase 1/2 study of KRd without ASCT9 to $50% after 8 cycles of
KRd with ASCT. This study size provided 10% type II error (90%
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Assessments

power) and a 5% type I error (2-sided) to detect an improvement
of the sCR rate to 50% compared with the historical sCR rate
of 30%.9

Results
Between 29 January 2013, and 4 November 2015, 76 patients
were enrolled and entered the induction phase. The data cutoff
was 1 May 2019. Median age was 59 years (range, 40 to
76 years), with 28% age 65 years or older (Table 1). High-risk
cytogenetic abnormalities according to IMWG criteria were
detected in 36% of patients, including 15% with del(17p) and
11% with ultra-high-risk MM ($3 cytogenetic abnormalities).27
Of the 76 patients, 64 completed 18 cycles of KRd (Figure 1).
Median duration of KRd treatment was 18 cycles (range, 3 to
18 cycles). Twelve patients (16%) discontinued treatment early
because of noncompliance (n 5 1), patient/investigator preference (n 5 3), disease progression (n 5 4), and AEs (n 5 4).
Seventy-two patients underwent stem cell collection with a
median yield of 8.2 3 106 cells/kg (range, 3.1-17.3 3 106
cells/kg), and 72 completed ASCT.

Efﬁcacy
After 4 cycles, 97% of patients achieved a partial response or
better, 73% a VGPR or better, 16% a CR or better, and 11% an
sCR. After transplantation, the rate for CR or better was 25%, and
it was 20% for sCR. At the primary end point (8 cycles of KRd),
rates for CR or better and sCR increased to 65% and 60% and
reached 79% and 76%, respectively, as best response in the ITT
population (Figure 2; Table 2). Median time to sCR was
11.9 months (range, 0.9-26.4 months) (Figure 3).
Among patients evaluated for MRD, the MRD-negative rate was
60% after 8 cycles, 70% after 18 cycles, and 81% as best response, with corresponding rates of 52%, 61%, and 70%, respectively, by mITT analysis (Figure 4). Sustained MRD-negative
status per IMWG25 was observed in 55% of patients in the mITT
population. Most patients (48 of 76) were continuing with
lenalidomide maintenance at the cutoff date, and of those

KRd PLUS TRANSPLANT FOR NDMM

Characteristic

n (%)*

Total no. of patients

76

Age, y
Median (range)
$65

59 (40-76)
21 (27.6)

Sex
Male
Female

45 (59.2)
31 (40.8)

ECOG performance status
0-1
Unknown

65 (85.5)
11 (14.5)

ISS stage
I
II
III
Unknown

31
31
10
4

(40.8)
(40.8)
(13.2)
(5.3)

Cytogenetic risk by FISH†
High
del(17p)
Ultra-high risk‡
Standard

27
11
8
49

(35.5)
(14.5)
(10.5)
(64.5)

Serum b2-microglobulin, mg/L
,3.5
$3.5
Unknown

45 (59.2)
24 (31.6
7 (9.2)

ECOG, Eastern Cooperative Oncology Group; FISH, ﬂuorescence in situ hybridization; ISS,
International Staging System.
*All data in the table are n (%), unless otherwise designated.
†Deﬁned per International Myeloma Working Group (IMWG): t(4;14), del(17p), t(14;16),
t(14;20), nonhyperdiploidy and gain(1q).
‡High, risk $3 cytogenetic abnormalities.27

completing the last landmark MRD evaluation at 3 years of
lenalidomide maintenance, 76% (22 of 29) were MRD negative.
After a median follow-up of 56.0 months (range, 2.9-75.1
months), median PFS and OS were not reached. The estimated
5-year PFS rate was 72% (95% CI, 60%-81%), and the 5-year OS
rate was 84% (95% CI, 71%-92%) (Figure 5A-B). Among
39 patients who were MRD negative, estimated 5-year PFS was
85% (95% CI, 69%-93%), and OS was 91% (95% CI, 75%-97%)
(Figure 5C-D).
Response rates were not statistically different by IMWG risk
status, with sCR as best response in 81% of patients (22 of 27)
with high-risk cytogenetics and 73% of patients (36 of 49)
considered standard risk (P 5 .58). In the mITT population, MRD
negativity was achieved by 72% of high-risk patients (13 of 18)
and 68% of standard-risk patients (26 of 38) at data cutoff.
Among 11 patients with del(17p), 8 achieved sCR, and 2 of
4 patients who were evaluable achieved an MRD-negative response. The 5-year PFS rate was 57% for high-risk and 81% for
standard-risk patients, and the 5-year OS rates were 72% and
92%, respectively (Figure 6A-B). For patients with high-risk
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For the primary efﬁcacy analysis, all patients were evaluated
except those who declined to receive ASCT for reasons other
than toxicity or efﬁcacy. Patients who received ,4 cycles of KRd
consolidation were evaluable for the primary end point. For all
other efﬁcacy analyses, including time-to-event end points and
safety, the results are based on the intent-to-treat (ITT) population, deﬁned as all patients who received at least 1 dose of
carﬁlzomib and lenalidomide. The MRD rate was estimated for
the evaluable population and for a modiﬁed ITT (mITT) population as described by Perrot et al.26 For mITT, patients who
failed to achieve a very good partial response (VGPR) or better or
who did not complete KRd treatment for any reason were
considered MRD positive, and patients who achieved a VGPR or
better but did not have evaluable MRD were excluded from
the analysis. To ensure adequate assessment of MRD, overenrollment was allowed. Continuous and categorical data
were summarized with descriptive statistics. Comparisons of
categorical data were conducted with a Fisher’s exact test. Timeto-event end points were estimated by the Kaplan-Meier
method with GraphPad Prism version 7.03 (La Jolla, CA). Statistical analyses were performed with SAS version 9.4 software.

Table 1. Baseline characteristics

87 patients enrolled

≥VGPR
11 not eligible
• 2 withdrew consent
• 1 Physician preference
• 8 Other

72 entered ASCT phase

4 discontinued KRd induction
• 1 Adverse event*
• 1 Disease progression
• 1 Non-compliance
• 1 Withdrew consent

84

80

79

75 74
65

60

76

60

40
25

20
0

2 discontinued KRd consolidation
• 1 Adverse event
• 1 Disease progression

20

After
ASCT
(n=76)

After
8 Cycles
(n=72)

After
18 Cycles
(n=76)

Best
Response
(n=76)

Figure 2. Response rates over the course of KRd plus ASCT treatment in ITT
population (n 5 76). After cycle 8 (n 5 72), the per protocol population excluded 2
patients who withdrew consent, 1 patient for noncompliance, and 1 patient for AE
unrelated to treatment. In the ITT population after cycle 8 (n 5 76), the response rate
for VGPR or better was 86%, for CR or better it was 62%, and for sCR it was 57%. nCR,
near complete response; PR, partial response.

64 completed KRd maintenance
76 analyzed for efﬁcacy and safety

Figure 1. Patient disposition. *AE unrelated to treatment in patient retrospectively
ineligible for the trial. †Discontinued on day 1104 after ASCT and before starting
KRd consolidation.

cytogenetics, MRD negativity was associated with improved PFS
compared with MRD-positive/MRD-unknown patients (P 5 .04)
with no signiﬁcant difference in OS (P 5 .26) (Figure 6C-D). For
patients who achieved MRD negativity, there was no statistically
signiﬁcant difference between those with high-risk cytogenetics
and those who had standard-risk cytogenetics for PFS (P 5 .31)
or for OS (P 5 .13).

Safety and tolerability
KRd treatment was well tolerated during the study. AEs were
manageable with dose modiﬁcations, with a rate of 76% for
carﬁlzomib, 66% for dexamethasone, and 71% for lenalidomide.
Four patients discontinued treatment because of AEs.
The most common AEs (all grades) were infection (74%), fatigue
(67%), and thrombocytopenia (62%) (Table 3). The most common grade 3 to 4 AEs were neutropenia (34%), lymphopenia
(32%), and infection (22%). Hypertension (all grades) was reported in 20% of patients, with 5% experiencing grade 3 to 4
hypertension. Forty-two percent of patients developed grade 1
to 2 peripheral neuropathy (7% grade 2); there were no grade 3
to 4 events. Cardiac events were infrequent (13%) and generally
moderate in severity (grade 1 to 2). Two patients experienced
asymptomatic decline of left ventricular ejection fraction to 45%
to 50% pre-transplant, and 1 patient experienced a transient
decline to 47% associated with hypertension during KRd
maintenance. There was 1 case of secondary primary malignancy
(acute myeloid leukemia) during the study, and one case of
thrombotic microangiopathy (thrombotic thrombocytopenic
purpura/hemolytic uremic syndrome), which developed within
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1 year of KRd completion and during lenalidomide maintenance.
There were no treatment-related deaths.

Discussion
In this single-arm, phase 2 study, patients with NDMM receiving
KRd with ASCT showed high rates of deep, durable responses.
After 8 cycles of KRd with ASCT, 65% of patients achieved CR or
better and 60% achieved sCR (primary end point). Extended KRd
maintenance after consolidation further improved depths of
response, with CR and sCR rates improving to 79% and 76% as
best response by ITT. High CR and sCR rates corresponded to
high MRD-negative rates, 70% by next-generation sequencing
at ,1025 sensitivity in the mITT population. These response
rates seem to exceed rates reported in studies of KRd without
transplantation9 and are among the highest rates in NDMM,
including those reported in recent studies with triplet combinations plus monoclonal antibodies with or without ASCT.12-14,18
After prolonged follow-up (median, 5 years), median PFS and OS
have still not been reached, with close to 70% of patients
free from progression at 5 years. For patients who achieved an

Table 2. Best response
Best overall response

KRd 1 ASCT, n (%) (n 5 76)

sCR

58 (76.3)

$CR

60 (78.9)

$nCR

67 (88.2)

$VGPR

69 (90.8)

$PR

74 (97.4)

nCR, near complete response; PR, partial response.
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70 entered KRd consolidation phase

4 discontinued KRd maintenance
• 2 Adverse events
• 1 Disease progression
• 1 Physician/patient preference

91

90
84

2 discontinued after ASCT
• 1 Withdrew consent
• 1 Disease progression†

68 entered KRd maintenance phase

sCR

100

Response, %

76 entered KRd induction
and mobilization

≥CR

Patients in response, %

100
80
60
≥PR
≥VGPR
≥nCR
≥CR
sCR

40
20
0
0

6

12

18

24

30

Figure 3. Time to response in respective response categories over time on
treatment in months. nCR, near complete response; PR, partial response.

MRD-negative response, the 5-year PFS was 85%, which was
signiﬁcantly higher than the PFS rate of 55% for MRD-positive/
MRD-unknown patients. The 5-year PFS rates of both MRDnegative and MRD-positive/MRD-unknown patients seem
higher than rates reported in previous studies with comparable
follow-up.17 This may reﬂect the depth of response across all
enrolled patients, with a rate for VGPR or better of 91%, indicating that regardless of MRD status, extended KRd with ASCT
is very effective.
The initial response to KRd was rapid, and responses continued
to improve beyond 12 months of treatment for many patients,
indicating that extended treatment with highly active multidrug
regimens are needed to achieve quality durable responses
across a spectrum of patients in an NDMM population. sCR
responses continued to increase beyond 8 cycles of treatment,
with a median time to sCR of 11.9 months; 42% of conversions to
sCR occurred 12 months after the start of KRd treatment, with an
upper range of 20 months. Although MRD conversion was not
assessed for each treatment cycle, MRD-negative rates also

The primary objective of the study was to evaluate the addition
of ASCT to KRd by using sCR rate at the end of KRd consolidation (total 8 KRd cycles) as the surrogate end point of efﬁcacy.
The sCR rate of 60% after a total of 8 cycles of KRd, exceeded the
predeﬁned threshold of 50%, which was based on the sCR rate of
30% after 8 cycles in a previous KRd study without ASCT.9 In
addition, extending treatment with KRd maintenance seemed to
improve multiple secondary end points compared with extended KRd without ASCT,9 including higher rates of sCR as best
response and MRD-negative disease, although there are important limitations with cross-study comparisons. In all, results of
this study support the premise that incorporating ASCT into
extended KRd can improve clinical outcomes, which supports
the need for further evaluation in the randomized setting.
The phase 2 FORTE trial randomly assigned patients with
NDMM to 8 cycles of KRd with ASCT, 12 cycles of KRd without
ASCT, or 8 cycles of carﬁlzomib-cyclophosphamide-dexamethasone (KCd) with ASCT, with a second random assignment
to KR or lenalidomide maintenance.15,28,29 Preliminary results
demonstrated that both KRd regimens outperformed KCd with
respect to sCR after consolidation, but there was no difference
between the KRd arms, which would seem to contradict our
premise that the addition of ASCT improves outcomes. In the
FORTE study, the rates for CR or sCR or better were 60% and
44% in KRd with ASCT after 8 cycles vs 61% and 43% in KRd
without ASCT after 12 cycles; the MRD-negative response rate
was 58% vs 54%, respectively.28 However, with the landmark

Evaluable Patients

mITT Population

100

100
81

60

60

40

20

0

80
70

70

MRD response, %

MRD response, %

80

60

61
52

40

20
n=44

n=43

n=48

Cycle 8

Cycle 18

Best response

0

n=50

n=51

n=56

Cycle 8

Cycle 18

Best response

Figure 4. MRD response rates over the course of KRd plus ASCT treatment. Forty-eight patients had baseline and at least 1 postbaseline bone marrow sample available for
MRD assessment by next-generation sequencing (clonoSeq). MRD rates at 8 cycles, at the end of 18 cycles of KRd, and best response in evaluable patients (patients with at least
1 MRD assessment) (A), and in mITT population (B) (as described by Perrot et al26 and in “Methods”).
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Months

increased at landmark time points; the increase between cycle 8
and 18 was relatively modest and may indicate that MRDnegative status in some patients can be reached earlier than
the clearance of M-protein. This reﬂects the predictive signiﬁcance of MRD and the established phenomenon of slower
clearance of M-protein than clonal plasma cells in bone marrow.
Overall, our results indicate that KRd treatment beyond 8 cycles
has the potential for deepening responses, possibly contributing
to the observed prolonged PFS at 5 years in the ITT population
and for both MRD-negative and MRD-positive/MRD-unknown
patients.
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Overall Survival
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Probability of survival
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76%
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20

Median FU

72%

60
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0
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100%
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56.0 mo
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100%
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60
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85%
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85%
55%

71
5
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6

66
6

59
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27
40
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Figure 5. PFS and OS in the ITT population. PFS and OS in the ITT population (A-B), and by MRD status (C-D). FU, follow-up; unk, unknown.

evaluation of KRd without ASCT at 12 cycles in the FORTE trial,
higher rates of CR or sCR or better and MRD are expected
compared with 8 cycles. An early analysis of the FORTE study
showed trends in response at landmark time points consistent
with this study: the rates of CR or better or sCR for KRd with ASCT
increased from 28% and 20% after ASCT to 50% and 41% after
8 cycles, whereas in the KRd without ASCT arm, the sCR rates
increased from 35% and 31% after 8 cycles to 52% and 42% after
12 cycles.15 We designed this study to compare the sCR rate
after 8 cycles of KRd with ASCT with the sCR rate after 8 cycles
from the historical study of KRd without ASCT.9 In addition, a
recent update from the FORTE trial showed a lower risk of early
relapse for KRd with ASCT compared with KRd without ASCT
and a higher rate of sustained MRD negativity, suggesting that
the addition of ASCT may improve treatment outcomes with
KRd,29,30 similar to results from the IFM2009 trial of RVd with and
without ASCT.17 Follow-up for PFS and OS is ongoing for the
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FORTE trial and will help to differentiate between KRd with and
without ASCT.
To understand the potential beneﬁt of extended KRd with ASCT,
toxicity risks also need to be carefully considered. Overall, KRd
with ASCT was well tolerated during induction and through
consolidation and maintenance. Treatment toxicity was managed with dose modiﬁcation, and discontinuations were infrequent. The types and rates of AEs in this study were consistent
with those from KRd without ASCT9 and with results from the
FORTE trial15; cytopenias and infections were the most common
grade 3 to 4 events. Peripheral neuropathy was reported in
almost half the patients, but most events were grade 1 in severity, with no grade 3 to 4 events. In a phase 2 study, the IFM
group reported 8 serious cardiovascular events in 44 patients
with NDMM who received KRd with ASCT.22 In the current study
and the FORTE trial,15 cardiovascular events were present but
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Table 3. Treatment-emergent AEs during KRd*
KRd 1 ASCT (n 5 76)
All grades,
n (%)

AE

Grade 3 to
4, n (%)

47
32
32
30

Nonhematologic
Infection
Fatigue

56 (74)
51 (67)

17 (22)
4 (5)

Diarrhea
Hyperglycemia
Dyspnoea
Peripheral neuropathy
Rash
Hypophosphatemia
Hypertension
Thromboembolic events
Cardiac events†

39
33
30
32
33
22
15
14
10

7 (9)
6 (8)
2 (3)
0
4 (5)
11 (14)
4 (5)
5 (7)
2 (3)

(62)
(42)
(42)
(39)

(51)
(43)
(39)
(42)
(43)
(29)
(20)
(18)
(13)

11
9
24
26

(14)
(12)
(32)
(34)

*AEs with rate of .10% for any grade; events during ASCT and single-agent lenalidomide
maintenance were not captured per protocol.
†Two patients had asymptomatic left ventricular ejection fraction of 45% to 50%
pretransplant, and one had a transient decline of left ventricular ejection fraction to 47%
associated with hypertension during KRd maintenance.

manageable. We need to better understand long-term risk with
KRd with ASCT in a broader patient population, and the safety
results from ongoing randomized trials with KRd should help
resolve these issues. Recently, the phase 3 ENDURANCE study,
which compared KRd with RVd in patients with NDMM not
undergoing ASCT, reported a higher rate of cardio-pulmonaryrenal events with KRd but a higher rate of peripheral neuropathy
with RVd.11 The ongoing phase 3 ATLAS trial (NCT02659293) will
compare the efﬁcacy and safety of maintenance therapy with
KRd vs lenalidomide after transplantation.
In this study, the best response rates by cytogenetic risk, including
sCR rates, were comparable, but PFS curves for high-risk and
standard-risk patients diverged after 24 months, reﬂecting differences in durability of response and resulting in a shorter median PFS
for the high-risk subgroup. However, PFS outcomes for high-risk
patients who achieved MRD-negative response (;50% of all highrisk patients [n 5 27]) were markedly improved compared with
MRD-positive/MRD-unknown high-risk patients and compared with
standard-risk patients. This observation is consistent with previous
observations from the GEM/PETHEMA Study Group which showed
MRD response was more relevant than CR in overcoming the
negative prognostic impact of high-risk cytogenetics.31 Considering
the relatively high rates of MRD negativity for high-risk patients in
this study, our results support further evaluation of extended KRd
with ASCT in high-risk patients, with or without the addition of novel
agents to achieve MRD-negativity.6,27,32,33
Several recent studies in NDMM have shown a clear beneﬁt of
adding antibodies (eg, daratumumab) to doublet and triplet
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Our results support strategies to further enhance active regimens,
with the objective of improving sCR and MRD-negative rates,
particularly for patients with high-risk disease. Whether ASCT or an
antibody added to a backbone of existing regimens, or both, would
ultimately be preferred will need to be sorted out and may include
response-adaptive strategies based on achievement of MRD
negativity and more active maintenance regimens. Given the improvement in MRD response with daratumumab in the GRIFFIN
study,18 its addition to KRd is of high interest, and preliminary results
of KRd-daratumumab regimens in NDMM have reported very high
MRD-negative rates (80% to 83% at ,1025 sensitivity).16,34,35
Moving forward, it will be important to better deﬁne which multidrug regimens to use as extended treatment backbones and in
which patients. Several studies have assessed RVd with ASCT. In the
phase 3 IFM2009 study, patients who received RVd-ASCT had
longer PFS compared with those who received RVd (50 vs
36 months), and a higher CR rate as best response (59% vs 48%).17
In a second phase 3 study, PETHEMA/GEM2012, patients were
randomly assigned to 2 different ASCT conditioning regimens with
all patients receiving RVd induction/consolidation; in a grouped
response analysis, the sCR rate was 44.5% after consolidation, with a
corresponding MRD-negative rate (,1026 sensitivity) of 45.2%.8
The results reported here and from other KRd studies9,15,22,36,37
support KRd for patients undergoing ASCT, but deﬁnitive
studies are needed to determine its role, particularly in relation
to RVd, in the current treatment landscape. The phase 3
ENDURANCE study compared KRd and RVd regimens in patients with NDMM, with no intention for immediate ASCT and
without high-risk disease.11 Patients were randomly assigned to
induction with KRd (9 cycles, 4 weeks per cycle) or RVd (12
cycles, 3 weeks per cycle), with a second random assignment to
indeﬁnite or 2 years of lenalidomide maintenance. Initial outcomes were recently presented, with no signiﬁcant difference in
the co-primary end point of PFS (median, 34.6 months for KRd vs
34.4 months for RVd), although KRd was associated with a higher
rate of VGPR or better after induction (73.8% vs 64.7%). Although these results support the view that there is no signiﬁcant
difference between KRd and RVd in NDMM, outcomes seem
inferior to results from other KRd studies to date, including in the
non-transplantation arm of the FORTE trial,9,15,36,37 as well as RVd
studies, including large randomized trials.2,7,17 At this point, it
is unclear whether the inconsistency of outcomes from the
ENDURANCE trial with historical studies may be related to differences in study design (eg, phase 2 vs phase 3), study populations, or
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regimens with and without ASCT.12-14,18 In the phase 3 CASSIOPEIA
study, the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation in
patients with NDMM undergoing ASCT signiﬁcantly improved
the sCR rate 100 days after ASCT to 29% compared with 20%
for patients who received VTd alone.14 Similarly, the addition of
daratumumab to RVd induction/consolidation (D-RVd) for patients with NDMM undergoing ASCT in the phase 2 GRIFFIN
study improved the sCR rate at the end of consolidation to
42.4% compared with 32.0% for RVd alone.18 Patients in the
D-RVd arm received D-R maintenance after consolidation whereas
those in the RVd arm received lenalidomide maintenance; after a
median follow-up of 22.1 months, the sCR rate was 62.6% with
D-RVd compared with 45.4% with RVd, and the MRD-negative rate
(,1025 sensitivity) was 51.0% compared with 20.4%.

relatively short durations of treatment in both arms, a potential key
driver of efﬁcacy with KRd in the current study. The ongoing randomized phase 3 COBRA study (NCT03729804) is comparing
extended KRd (24 cycles)9 with the established RVd regimen (8
cycles with lenalidomide maintenance),2,17 both arms allowing highrisk patients and candidates for transplantation but with deferred
ASCT. More recently, investigators initiated the phase 2 ADVANCE
study (NCT04268498), which will randomly assign patients with
NDMM to RVd, KRd, or D-KRd. Taken together, these studies, as
well as the ongoing FORTE and ATLAS trials, should help to better
deﬁne a preferred regimen in NDMM and for which patient population, and which regimen or strategy will be more suitable for
making further progress toward elimination of the disease.

In summary, results from the phase 2 study reported here
demonstrate that patients treated with extended KRd with ASCT
achieved high rates of sCR and MRD-negative disease with
prolonged PFS and OS. The sCR rate after KRd consolidation
met the primary end point, with responses continuing to improve
during KRd maintenance. In addition, we observed that KRd with
ASCT generates high rates of MRD negativity in both high-risk
and standard-risk patients, and that the achievement of MRDnegative response in high-risk patients is associated with
improved outcomes, comparable to those of standard-risk patients. Safety and tolerability were acceptable and manageable.
Overall, results from this study, together with those of other KRd
studies,9,22,36 support ongoing and future evaluations of extended KRd with and without ASCT in the randomized setting.
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In the era of highly active triplet and now quadruplet combinations,
differentiating between treatment regimens in general NDMM
populations with standard survival end points may prove to be increasingly challenging, which highlights the need for surrogate
markers. MRD is emerging as a likely surrogate candidate, because
multiple studies have demonstrated strong association between
MRD status and survival outcomes.8,14,17,18 Several ongoing randomized trials, including the ADVANCE study, have already adopted
MRD as a primary end point, and regulatory agencies are considering
MRD as a surrogate end point. There are also efforts to adopt
risk- and MRD-adaptive treatment strategies for intensiﬁcation
and/or extending treatment duration as well as de-escalation or
discontinuation.16,38,39 MRD-negative response, or preferably
sustained MRD-negative response, could be used to inform
treatment of standard-risk patients in whom extended multidrug regimens or even ASCT may not be of beneﬁt, or conversely, for high-risk patients who may require longer multidrug
treatment to achieve sustained MRD response or the addition
of novel agents.31 Whether ASCT or an antibody, or both,
should be added to a backbone of existing regimens along with
duration of treatment will ultimately need to be sorted out in
ongoing and future prospective randomized trials.
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